226 related articles for article (PubMed ID: 15909255)
41. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.
Pandey BD; Pandey K; Kaneko O; Yanagi T; Hirayama K
Am J Trop Med Hyg; 2009 Apr; 80(4):580-2. PubMed ID: 19346379
[TBL] [Abstract][Full Text] [Related]
42. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Seifert K; Croft SL
Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
[TBL] [Abstract][Full Text] [Related]
43. Cutaneous leishmaniasis with lymphadenopathy due to Leishmania donovani.
Faber WR; Wonders J; Jensema AJ; Chocholova E; Kager PA
Clin Exp Dermatol; 2009 Jul; 34(5):e196-8. PubMed ID: 19077092
[TBL] [Abstract][Full Text] [Related]
44. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
Dorlo TP; Balasegaram M; Beijnen JH; de Vries PJ
J Antimicrob Chemother; 2012 Nov; 67(11):2576-97. PubMed ID: 22833634
[TBL] [Abstract][Full Text] [Related]
45. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
Ramesh V; Ansari NA; Jain RK; Salotra P
Clin Exp Dermatol; 2008 Jan; 33(1):103-5. PubMed ID: 17979988
[No Abstract] [Full Text] [Related]
46. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
[TBL] [Abstract][Full Text] [Related]
47. Chronic cutaneous leishmaniasis in an immunocompetent patient: response to miltefosine.
Ruiz-Villaverde R; Sánchez-Cano D; Villaverde-Gutierrez C
J Eur Acad Dermatol Venereol; 2007 May; 21(5):695-6. PubMed ID: 17447994
[No Abstract] [Full Text] [Related]
48. Diffuse (anergic) cutaneous leishmaniasis responding to amphotericin B.
Morrison B; Mendoza I; Delgado D; Reyes Jaimes O; Aranzazu N; Paniz Mondolfi AE
Clin Exp Dermatol; 2010 Jun; 35(4):e116-9. PubMed ID: 19886959
[TBL] [Abstract][Full Text] [Related]
49. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
Soto J; Toledo J; Gutierrez P; Nicholls RS; Padilla J; Engel J; Fischer C; Voss A; Berman J
Clin Infect Dis; 2001 Oct; 33(7):E57-61. PubMed ID: 11528586
[TBL] [Abstract][Full Text] [Related]
50. [Oral miltefosine to treat leishmaniasis].
Soto J; Soto P
Biomedica; 2006 Oct; 26 Suppl 1():207-17. PubMed ID: 17361856
[TBL] [Abstract][Full Text] [Related]
51. New World and Old World Leishmania Infections: A Practical Review.
Kevric I; Cappel MA; Keeling JH
Dermatol Clin; 2015 Jul; 33(3):579-93. PubMed ID: 26143433
[TBL] [Abstract][Full Text] [Related]
52. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Croft SL; Engel J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
[TBL] [Abstract][Full Text] [Related]
53. [Disseminated cutaneous leishmaniasis in a case of an immunodepressed woman].
Venencie PY; Bourée P; Hiesse C; Vieillefond A; Lantz O; Doukan S; Rioux JA
Ann Dermatol Venereol; 1993; 120(6-7):461-3. PubMed ID: 8279793
[TBL] [Abstract][Full Text] [Related]
54. First case of typical Old World cutaneous leishmaniasis treated with miltefosine.
Stojkovic M; Junghanss T; Krause E; Davidson RN
Int J Dermatol; 2007 Apr; 46(4):385-7. PubMed ID: 17442078
[TBL] [Abstract][Full Text] [Related]
55. Diffuse cutaneous leishmaniasis in an HIV-positive patient in western Africa.
Niamba P; Goumbri-Lompo O; Traoré A; Barro-Traoré F; Soudré RT
Australas J Dermatol; 2007 Feb; 48(1):32-4. PubMed ID: 17222299
[TBL] [Abstract][Full Text] [Related]
56. Miltefosine for Indian visceral leishmaniasis.
Roca B
N Engl J Med; 2003 Feb; 348(9):857-8; author reply 857-8. PubMed ID: 12608397
[No Abstract] [Full Text] [Related]
57. Disseminated cutaneous leishmaniasis due to Leishmania guyanensis: case of a patient with 425 lesions.
Couppié P; Clyti E; Sainte-Marie D; Dedet JP; Carme B; Pradinaud R
Am J Trop Med Hyg; 2004 Nov; 71(5):558-60. PubMed ID: 15569784
[TBL] [Abstract][Full Text] [Related]
58. Diffuse cutaneous leishmaniasis and HIV co-infection: A case report and review of the literature.
Kassardjian AA; Yim KM; Rabi S; Liang TZ; Kim GH; Ochoa MT; Sattah MV; Ahronowitz IZ
J Cutan Pathol; 2021 Jun; 48(6):802-806. PubMed ID: 33611800
[No Abstract] [Full Text] [Related]
59. Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature.
Collini P; Premchand N; Lockwood D; Greig J
Ann Trop Med Parasitol; 2009 Jul; 103(5):455-9. PubMed ID: 19583915
[No Abstract] [Full Text] [Related]
60. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
